Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease.
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
Anemia, Sickle Cell
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.
NF-?B is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors.
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.
Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease.
Sudden death in sickle cell disease: current experience.
Anemia Sickle Cell